APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemophilia AAV Gene Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hemophilia AAV Gene Therapy Market Outlook and Growth Opportunities 2026

26 December 2025196 pages

Choose your research edition.

Industry ResearchHemophilia AAV Gene Therapy Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemophilia AAV Gene Therapy Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal Hemophilia AAV Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemophilia AAV Gene Therapy Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemophilia AAV Gene Therapy Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Hemophilia AAV Gene Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hemophilia AAV Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hemophilia AAV Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hemophilia AAV Gene Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hemophilia AAV Gene Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hemophilia AAV Gene Therapy market include Pfizer, CSL/uniQure (Hemgenix&Glybera) and BioMarin (Roctavian), among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Hemophilia AAV Gene Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hemophilia AAV Gene Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hemophilia AAV Gene Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Hemophilia AAV Gene Therapy market.

Hemophilia AAV Gene Therapy Segment by Company

Pfizer

CSL/uniQure (Hemgenix&Glybera)

BioMarin (Roctavian)

Hemophilia AAV Gene Therapy Segment by Type

AVV5 Vector

AAVrh74 Vector

Hemophilia AAV Gene Therapy Segment by Application

Hemophilia A

Hemophilia B

Hemophilia AAV Gene Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hemophilia AAV Gene Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Hemophilia AAV Gene Therapy key companies, revenue, market share, and recent developments.

3. To split the Hemophilia AAV Gene Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Hemophilia AAV Gene Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hemophilia AAV Gene Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Hemophilia AAV Gene Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia AAV Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemophilia AAV Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia AAV Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hemophilia AAV Gene Therapy industry.

Chapter 3: Detailed analysis of Hemophilia AAV Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Hemophilia AAV Gene Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Hemophilia AAV Gene Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hemophilia AAV Gene Therapy Industry Trends Table 2. Hemophilia AAV Gene Therapy Industry Drivers Table 3. Hemophilia AAV Gene Therapy Industry Opportunities and Challenges Table 4. Hemophilia AAV Gene Therapy Industry Restraints Table 5. Global Hemophilia AAV Gene Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hemophilia AAV Gene Therapy Revenue Share by Company (2021-2026) Table 7. Global Hemophilia AAV Gene Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Hemophilia AAV Gene Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Hemophilia AAV Gene Therapy Company, Product Type & Application Table 10. Global Hemophilia AAV Gene Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Hemophilia AAV Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of AVV5 Vector Table 15. Significant Companies of AAVrh74 Vector Table 16. Global Hemophilia AAV Gene Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Hemophilia AAV Gene Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Hemophilia AAV Gene Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Hemophilia AAV Gene Therapy Sales Value Share by Type (2021-2026) Table 20. Global Hemophilia AAV Gene Therapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hemophilia A Table 22. Significant Companies of Hemophilia B Table 23. Global Hemophilia AAV Gene Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Hemophilia AAV Gene Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Hemophilia AAV Gene Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Hemophilia AAV Gene Therapy Sales Value Share by Application (2021-2026) Table 27. Global Hemophilia AAV Gene Therapy Sales Value Share by Application (2027-2032) Table 28. Global Hemophilia AAV Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Hemophilia AAV Gene Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Hemophilia AAV Gene Therapy Sales Value Share by Region (2021-2026) Table 31. Global Hemophilia AAV Gene Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Hemophilia AAV Gene Therapy Sales Value Share by Region (2027-2032) Table 33. Global Hemophilia AAV Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Hemophilia AAV Gene Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Hemophilia AAV Gene Therapy Sales Value Market Share by Country (2021-2026) Table 36. Global Hemophilia AAV Gene Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Hemophilia AAV Gene Therapy Sales Value Market Share by Country (2027-2032) Table 38. Pfizer Company Information Table 39. Pfizer Business Overview Table 40. Pfizer Hemophilia AAV Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Pfizer Hemophilia AAV Gene Therapy Product Portfolio Table 42. Pfizer Recent Development Table 43. CSL/uniQure (Hemgenix&Glybera) Company Information Table 44. CSL/uniQure (Hemgenix&Glybera) Business Overview Table 45. CSL/uniQure (Hemgenix&Glybera) Hemophilia AAV Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. CSL/uniQure (Hemgenix&Glybera) Hemophilia AAV Gene Therapy Product Portfolio Table 47. CSL/uniQure (Hemgenix&Glybera) Recent Development Table 48. BioMarin (Roctavian) Company Information Table 49. BioMarin (Roctavian) Business Overview Table 50. BioMarin (Roctavian) Hemophilia AAV Gene Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. BioMarin (Roctavian) Hemophilia AAV Gene Therapy Product Portfolio Table 52. BioMarin (Roctavian) Recent Development Table 53. Research Programs/Design for This Report Table 54. Authors List of This Report Table 55. Secondary Sources Table 56. Primary Sources List of Figures Figure 1. Hemophilia AAV Gene Therapy Product Image Figure 2. Global Hemophilia AAV Gene Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemophilia AAV Gene Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Hemophilia AAV Gene Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. AVV5 Vector Image Figure 8. AAVrh74 Vector Image Figure 9. Global Hemophilia AAV Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Hemophilia AAV Gene Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Hemophilia AAV Gene Therapy Sales Value Share by Type (2021-2032) Figure 12. Hemophilia A Image Figure 13. Hemophilia B Image Figure 14. Global Hemophilia AAV Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Hemophilia AAV Gene Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Hemophilia AAV Gene Therapy Sales Value Share by Application (2021-2032) Figure 17. Global Hemophilia AAV Gene Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Hemophilia AAV Gene Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Hemophilia AAV Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 20. North America Hemophilia AAV Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Hemophilia AAV Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Hemophilia AAV Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Hemophilia AAV Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Hemophilia AAV Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Hemophilia AAV Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 26. South America Hemophilia AAV Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Hemophilia AAV Gene Therapy Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Hemophilia AAV Gene Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • AVV5 Vector
  • AAVrh74 Vector
Applications
  • Hemophilia A
  • Hemophilia B
Companies covered
  • Pfizer
  • CSL/uniQure (Hemgenix&Glybera)
  • BioMarin (Roctavian)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hemophilia AAV Gene Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hemophilia AAV Gene Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Hemophilia AAV Gene Therapy Market Dynamics
  1. 2.1 Hemophilia AAV Gene Therapy Industry Trends
  2. 2.2 Hemophilia AAV Gene Therapy Industry Drivers
  3. 2.3 Hemophilia AAV Gene Therapy Industry Opportunities and Challenges
  4. 2.4 Hemophilia AAV Gene Therapy Industry Restraints
3 Hemophilia AAV Gene Therapy Market by Company
  1. 3.1 Global Hemophilia AAV Gene Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Hemophilia AAV Gene Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Hemophilia AAV Gene Therapy Company Ranking (2024-2026)
  4. 3.4 Global Hemophilia AAV Gene Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Hemophilia AAV Gene Therapy Company Product Type and Application
  6. 3.6 Global Hemophilia AAV Gene Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Hemophilia AAV Gene Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Hemophilia AAV Gene Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Hemophilia AAV Gene Therapy Market by Type
  1. 4.1 Hemophilia AAV Gene Therapy Type Introduction
  2. 4.1.1 AVV5 Vector
  3. 4.1.2 AAVrh74 Vector
  4. 4.2 Global Hemophilia AAV Gene Therapy Sales Value by Type
  5. 4.2.1 Global Hemophilia AAV Gene Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hemophilia AAV Gene Therapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global Hemophilia AAV Gene Therapy Sales Value Share by Type (2021-2032)
5 Hemophilia AAV Gene Therapy Market by Application
  1. 5.1 Hemophilia AAV Gene Therapy Application Introduction
  2. 5.1.1 Hemophilia A
  3. 5.1.2 Hemophilia B
  4. 5.2 Global Hemophilia AAV Gene Therapy Sales Value by Application
  5. 5.2.1 Global Hemophilia AAV Gene Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Hemophilia AAV Gene Therapy Sales Value by Application (2021-2032)
  7. 5.2.3 Global Hemophilia AAV Gene Therapy Sales Value Share by Application (2021-2032)
6 Hemophilia AAV Gene Therapy Regional Value Analysis
  1. 6.1 Global Hemophilia AAV Gene Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hemophilia AAV Gene Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Hemophilia AAV Gene Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Hemophilia AAV Gene Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hemophilia AAV Gene Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Hemophilia AAV Gene Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Hemophilia AAV Gene Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Hemophilia AAV Gene Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Hemophilia AAV Gene Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Hemophilia AAV Gene Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Hemophilia AAV Gene Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Hemophilia AAV Gene Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Hemophilia AAV Gene Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Hemophilia AAV Gene Therapy Sales Value Share by Country, 2025 VS 2032
7 Hemophilia AAV Gene Therapy Country-level Value Analysis
  1. 7.1 Global Hemophilia AAV Gene Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hemophilia AAV Gene Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Hemophilia AAV Gene Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Hemophilia AAV Gene Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Hemophilia AAV Gene Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Hemophilia AAV Gene Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Hemophilia AAV Gene Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Hemophilia AAV Gene Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Hemophilia AAV Gene Therapy Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 CSL/uniQure (Hemgenix&Glybera)
  8. 8.2.1 CSL/uniQure (Hemgenix&Glybera) Company Information
  9. 8.2.2 CSL/uniQure (Hemgenix&Glybera) Business Overview
  10. 8.2.3 CSL/uniQure (Hemgenix&Glybera) Hemophilia AAV Gene Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CSL/uniQure (Hemgenix&Glybera) Hemophilia AAV Gene Therapy Product Portfolio
  12. 8.2.5 CSL/uniQure (Hemgenix&Glybera) Recent Developments
  13. 8.3 BioMarin (Roctavian)
  14. 8.3.1 BioMarin (Roctavian) Company Information
  15. 8.3.2 BioMarin (Roctavian) Business Overview
  16. 8.3.3 BioMarin (Roctavian) Hemophilia AAV Gene Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 BioMarin (Roctavian) Hemophilia AAV Gene Therapy Product Portfolio
  18. 8.3.5 BioMarin (Roctavian) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst